Psychedelics are going mainstream, rushing from academic research and the underground into billion-dollar companies listed on NASDAQ and the NYSE. Meanwhile cannabis-based medicines are booming with a recent $7.2B acquisition. With both sectors rapidly shifting from stigma to big business, much of the value is coming from patents. Will the next blockbuster drugs derive from cannabis or psychedelics, and how will they be protected? We discuss the different compounds being patented, the strategies companies are taking to patent them, and the emerging controversies over patenting and ownership of plant medicines.

Groovy or square? Patenting psychedelics, pot, and plant medicines

ACS Spring 2022

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.